bpc-157 toxicity animal studies as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Stable Gastric Pentadecapeptide BPC 157
Description
Whats the difference between systemic and localized administration in studies
Approximately 20 to 30 percent of users treating these conditions report disappointing results
hyperemia/hemorrhage was graded from focal to diffuse according to lamina propria or subendothelial localisation
The commonly referenced therapeutic range of 0.25-0.5 mg daily (250-500 mcg) extrapolates from the effective rat dose of approximately 10 mcg/kg body weight
